Latest Regulatory News

Range International Limited delivered a standout Q4 2024 with record sales revenue from its Re>Pal Indonesia operations, alongside improved margins and positive cash flow, signaling a robust turnaround.

Island Pharmaceuticals has enrolled all subjects in the Phase 2b arm of its ISLA-101 dengue fever clinical trial, advancing its antiviral drug development with key results expected in 2025.

Element 25 Limited has announced a 107% increase in Ore Reserves at its Butcherbird Manganese Project in Western Australia, now supporting an 18.3-year mine life at 1.1Mtpa production. This milestone underpins the company’s strategic expansion into battery-grade manganese supply for the EV market.

Archer Materials has been granted a pivotal US patent for its Biochip technology, safeguarding its intellectual property and positioning the company for strategic entry into the lucrative US medical diagnostics market.

Viridis Mining and Minerals has announced a substantial upgrade to its Colossus Ionic Adsorption Clay Rare Earth Element Project, reporting a 140% increase in its JORC-compliant Mineral Resource Estimate. This positions Colossus as the largest and highest-grade IAC rare earth resource globally, with significant implications for the rare earth sector.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Aeris Resources has completed a 70-hole drill program at its Constellation deposit, delivering impressive high-grade copper intercepts and setting the stage for a significant resource upgrade and mine permitting milestones.

Bell Financial Group has secured a significant agreement with Macquarie Bank to transfer approximately 75,000 online trading accounts, positioning Bell Direct and Desktop Broker for growth and earnings uplift in FY 2025.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

Evolution Mining delivered a standout December quarter with record cash flows, improved safety, and regulatory approval extending Cowal’s mine life to 2042. The company’s growth projects, including the Mungari mill expansion, are progressing ahead of schedule and under budget, positioning Evolution strongly for FY25.